Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine
1988
Enhancing Cancer Treatment with Hydralazine and Melphalan
Sample size: 19
publication
Evidence: high
Author Information
Author(s): I.J. Stratford, G.E. Adams, J. Godden, J. Nolan, N. Howells, N. Timpson
Primary Institution: MRC Radiobiology Unit
Hypothesis
Does hydralazine enhance the anti-tumor effect of melphalan in KHT tumors in mice?
Conclusion
Hydralazine significantly increases the anti-tumor effect of melphalan with minimal systemic toxicity.
Supporting Evidence
- Hydralazine increased the anti-tumor effect of melphalan with an enhancement ratio of 2.35.
- The combination of hydralazine and melphalan showed minimal increase in systemic toxicity.
- Hydralazine treatment resulted in significant tumor hypoxia, which was not the sole factor for enhanced melphalan efficacy.
- Hydralazine did not affect the number of cells recovered from KHT tumors.
Takeaway
Using hydralazine with melphalan helps fight cancer better while hurting healthy parts of the body less.
Methodology
Mice with KHT tumors were treated with melphalan and hydralazine, and tumor response was measured using growth delay and cell survival assays.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Male C3H/He mice, aged 8-12 weeks.
Statistical Information
P-Value
p<0.05
Confidence Interval
(1.2-0.83)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website